Exact Mass: 559.14

Exact Mass Matches: 559.14

Found 68 metabolites which its exact mass value is equals to given mass value 559.14, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

dTDP-D-desosamine

dTDP-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-D-glucose; dTDP-alpha-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucose; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucopyranose

C18H31N3O13P2 (559.1332)

dTDP-L-megosamine

C18H31N3O13P2 (559.1332)

dTDP-beta-L-evernosamine

dTDP-beta-L-evernosamine; dTDP-3-amino-2,3,6-trideoxy-3-C-methyl-4-O-methyl-beta-L-arabino-hexopyranose

C18H31N3O13P2 (559.1332)

Neoacrimarine K

1-hydroxy-4-[8-(2-hydroxypropan-2-yl)-2-oxo-2H,8H,9H-furo[2,3-h]chromen-9-yl]-3,5,6-trimethoxy-10-methyl-9,10-dihydroacridin-9-one

C31H29NO9 (559.1842)

Neoacrimarine K is found in citrus. Neoacrimarine K is an alkaloid from the roots of Citrus paradisi (grapefruit). Alkaloid from the roots of Citrus paradisi (grapefruit). Neoacrimarine K is found in citrus.

Gadoteridol

3-methyl-16,19,24-trioxo-2,17,18,25-tetraoxa-5lambda5,8lambda5,11lambda5,14lambda5-tetraaza-1-gadolinaoctacyclo[9.6.3.3^{1,8}.2^{5,14}.0^{1,5}.0^{1,8}.0^{1,11}.0^{1,14}]pentacosan-2-ium-5,8,11,14-tetrakis(ylium)-1,1-diuide

C17H29GdN4O7 (559.1277)

Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

Infigratinib

N-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-N-methylcarbamimidic acid

C26H31Cl2N7O3 (559.1865)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents

Acetic acid, 2-(4-((5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol-1-yl)sulfonyl)phenoxy)-

C25H25N3O8S2 (559.1083)

8-(5-Chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide

5-Chloro-N-[1-(4-fluorophenyl)-3-(C-hydroxycarbonimidoyl)-1H,4H,5H-benzo[g]indazol-8-yl]-2-(4-methylpiperazin-1-yl)pyridine-4-carboximidate

C29H27ClFN7O2 (559.1899)

Lamellarin I

C31H29NO9 (559.1842)

C20H33NO17

C20H33NO17 (559.1748)

Tetra-Ac-Antibiotic A 33853

C28H21N3O10 (559.1227)

convolutamide A|N-Tetradecanoyl-Deacylconvolutamide

C24H35Br2NO4 (559.0933)

leporizine B

C25H25N3O8S2 (559.1083)

Cys Asp His Trp

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid